⌘K
t
PDMR Dealing
Oxford, UK - 7 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group, was informed that Matthew Treagus, Chief Information Officer, has purchased 1,390 ordinary shares of 50p each ("Ordinary Shares") in the Company on 7 October 2022 on the London Stock Exchange at a price of 355.6655p. Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.00006% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR") |
|||||
|
a) |
Name |
Matthew Treagus |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Information Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Purchase |
||||
|
c) |
Price(s) and volumes(s) |
|
||||
|
d) |
Aggregated information · Aggregated volume · Aggregated total
|
1,390
£4,943.75
|
||||
|
e) |
Date of the transaction |
07-10-2022 |
||||
|
f) |
Place of the transaction |
London Stock Exchange, Main Market (XLON) |
||||
-Ends-
|
For further information, please contact: |
|
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Further information is available at www.oxb.com.
Generating summary...
| Date | 7 Oct 2022 |
| Time | 12:28:28 |
| Category | Director/PDMR dealings |
| ID | 2105C |